Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curasept Afterapid is a line of topical oral healthcare products, classified as Class 1 medical devices, developed by Curasept S.p.A. for the treatment of oral lesions including mouth ulcers, aphthous ulcers, and stomatitis. The formulation features a synergistic blend of mucoadhesive polymers, hydrolyzed DNA and RNA to accelerate tissue regeneration, and Biomoist hyaluronic acid to form a protective, moisturizing film. Additional active components include tea tree and manuka oils for antimicrobial properties, 18β-glycyrrhetinic acid for anti-inflammatory effects, ruscogenin for its astringent qualities, and allantoin and bisabolol to soothe and promote cell proliferation. Available as a mouthwash, gel, or spray, the product line is designed to provide rapid pain relief and speed up the natural healing process without the use of alcohol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curasept Afterapid.